







781, Industrial Area, Phase-II, Chandigarh - 160 002 INDIA Ph.: 0172- 4680800, 2638781

Fax: 0172-2652242

E-mail: corporate@indswift.com CIN No.: L24230CH1986PLC006897

Ref.:ISL:CH:2025

The President, Corporate Relationship Department, BSE Limited, Phiroze Jeejeebhoy Towers, 25<sup>th</sup> Floor, Dalal Street, Mumbai 400 001 Date: 20th February, 2025

The Vice President, National Stock Exchange of India Limited, Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/2, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai 400 051

**BSE Scrip Code: 524652** 

**NSE Symbol: INDSWFTLTD** 

SUB: INTIMATION UNDER REGULATION 30 OF THE SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015- APPOINTMENT OF SENIOR MANAGEMENT PERSONNEL

Dear Sir/Ma'am,

Pursuant to Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Mr. Anil Agrawal, has been appointed as "Chief Operating Officer (COO)" of the Company w.e.f. 20<sup>th</sup> February, 2025.

The information required to be disclosed under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed as Annexure I.

We request you to take the above information on record.

Thanking you,

For IND SWIFT LIMITED

PUNEET

Gight's graph to (MITT GARMAN

ACCORDANGE AND ACCORDANGE A

PUNEET KHURANA COMPANY SECRETARY & COMPLIANCE OFFICER













781, Industrial Area, Phase-II, Chandigarh - 160 002 INDIA Ph.: 0172- 4680800, 2638781

Fax: 0172-2652242

E-mail: corporate@indswift.com CIN No.: L24230CH1986PLC006897

## (Annexure I)

Name of the Senior	Mr. Anil Agrawal
Management	
Personnel	
Date of	20 <sup>th</sup> February, 2025
Appointment	
Reason for change	Appointment w.e.f 20.02.2025
Brief Profile	Mr. Anil Agrawal is a seasoned professional with a Bachelor of Pharmacy degree from Devi Ahilya Vishwavidyalaya, Indore, MP. He has a rich and diverse experience of more than 25 years in leading pharmaceutical operations at some of the most reputed organizations in the industry. His distinguished career includes leadership roles at Ranbaxy Laboratories Ltd, Dr. Reddy's Laboratories Ltd, Glenmark Pharmaceuticals Ltd, GlaxoSmithKline Pharmaceuticals Ltd, Zydus Cadila Healthcare Ltd, Alembic Pharmaceuticals Ltd, Par Formulations, and Sun Pharmaceutical Industries Ltd.  His extensive expertise in pharmaceutical manufacturing, operational efficiencies, and business transformation will be invaluable in elevating our formulation business to new heights.
Disclosure of Relationship between Directors	NA





